STOCK TITAN
  1. Home
  2. News
  3. BNTX

BioNTech SE American Depositary Share - BNTX STOCK NEWS

Welcome to our dedicated page for BioNTech SE American Depositary Share news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech SE American Depositary Share stock.

BioNTech SE (American Depositary Share - BNTX) is a leading biotechnology company based in Germany, renowned for its pioneering work in the field of immunotherapy and vaccines. BioNTech's core business revolves around developing innovative cancer treatments and vaccines for infectious diseases, including the widely recognized COVID-19 vaccine, Comirnaty, which it co-developed with Pfizer.

BioNTech's oncology pipeline encompasses several advanced drug classes, including mRNA-based drugs that encode antigens, neoantigens, cytokines, and antibodies. The company is also advancing cell therapies, bispecific antibodies, and antibody-drug conjugates, positioning itself at the forefront of cancer treatment innovation.

Partnerships play a crucial role in BioNTech's strategy. The company collaborates with major pharmaceutical giants such as Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, leveraging shared expertise to accelerate the development and commercialization of its therapies. Recent strategic collaborations include an agreement with MediLink Therapeutics to utilize their TMALIN® antibody-drug conjugate platform, enhancing BioNTech's capabilities in targeting novel cancer therapeutics.

BioNTech's financial health is robust, bolstered by the commercial success of Comirnaty and ongoing strategic partnerships. The company's commitment to innovation and excellence is reflected in its continuous efforts to develop new therapeutics and vaccines, ensuring significant contributions to global healthcare.

For more detailed information, visit the company's official website at www.BioNTech.com.

News

BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update

Rhea-AI Summary
BioNTech reports positive clinical data updates and progress in its oncology pipeline. The company also announces successful launches of its COVID-19 vaccine. However, it reduces its 2023 revenue guidance and R&D expenses. For the first nine months of 2023, BioNTech reports revenues of €2.3 billion, net profit of €472 million, and diluted earnings per share of €1.94 ($2.113).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
earnings
-
News

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

Rhea-AI Summary
Pfizer and BioNTech announce positive results from Phase 1/2 study of mRNA-based combination vaccine candidates for influenza and COVID-19. Lead formulations show robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. Phase 3 trial to start soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
covid-19
-
News

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

Rhea-AI Summary
BioNTech announces follow-up data from Phase 1/2 trial of CAR-T cell therapy candidate BNT211, showing encouraging signs of clinical activity and increased persistence of cancer-specific CAR-T cells when combined with CARVac.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
clinical trial
News

BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023

Rhea-AI Summary
BioNTech to announce financial results for Q3 2023 and host Innovation Series
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences earnings
-
News

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Rhea-AI Summary
BioNTech initiates Phase 2 clinical trial for autogene cevumeran in pancreatic cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
clinical trial
-
News

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate

Rhea-AI Summary
MediLink Therapeutics enters strategic collaboration with BioNTech for the development of next-generation antibody-drug conjugate candidate
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
News

Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine

Rhea-AI Summary
Health Canada has authorized the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for ages 6 months and older in Canada. The updated vaccine will be available as a single dose for individuals 5 years and older, regardless of prior vaccination history. For children 6 months through 4 years, it is authorized as a three-dose series or a single dose depending on vaccination history. The vaccine is expected to be available in the coming weeks. Pfizer and BioNTech continue to monitor emerging strains and conduct studies on vaccine effectiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
covid-19
-
News

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

Rhea-AI Summary
BioNTech and CEPI announce strategic partnership for the development of mRNA-based vaccine candidates for mpox
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
partnership
-
News

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Rhea-AI Summary
FDA approves Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine for individuals 12 years and older
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
fda approval covid-19
News

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

Rhea-AI Summary
Pfizer and BioNTech's COVID-19 vaccine tailored to the Omicron XBB.1.5 sublineage receives recommendation for marketing authorization in the EU
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
covid-19

FAQ

What is the current stock price of BioNTech SE American Depositary Share (BNTX)?

The current stock price of BioNTech SE American Depositary Share (BNTX) is $108.23 as of November 21, 2024.

What is the market cap of BioNTech SE American Depositary Share (BNTX)?

The market cap of BioNTech SE American Depositary Share (BNTX) is approximately 24.9B.

What does BioNTech SE do?

BioNTech SE is a biotechnology company focused on developing cancer immunotherapies and vaccines for infectious diseases, including COVID-19.

Where is BioNTech SE based?

BioNTech SE is based in Germany.

What is BioNTech's most well-known product?

BioNTech's most well-known product is the COVID-19 vaccine, Comirnaty, developed in collaboration with Pfizer.

Who are BioNTech's major partners?

BioNTech collaborates with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab.

What types of cancer therapies is BioNTech developing?

BioNTech is developing a variety of cancer therapies, including mRNA-based drugs, cell therapies, bispecific antibodies, and antibody-drug conjugates.

What is the TMALIN® platform?

The TMALIN® platform is an antibody-drug conjugate technology developed by MediLink Therapeutics, used by BioNTech for cancer therapeutics.

How can investors find more information about BioNTech?

Investors can find more information on BioNTech's official website or by contacting their investor relations team.

What recent collaboration has BioNTech announced?

BioNTech recently announced a strategic collaboration with MediLink Therapeutics to use their TMALIN® antibody-drug conjugate platform for novel cancer targets.

What is BioNTech's role in the fight against COVID-19?

BioNTech developed the COVID-19 vaccine Comirnaty in collaboration with Pfizer, which has become a critical tool in combating the pandemic.

Where can I find BioNTech's latest news and updates?

BioNTech's latest news and updates can be found on their official website and through their media relations contacts.

Stock BNTX logo
BioNTech SE American Depositary Share

Nasdaq:BNTX

BNTX Rankings

#468 Ranked by Market Cap
N/A Ranked by Dividends

BNTX Stock Data

24.91B
90.26M
62.31%
20.65%
0.84%
Biotechnology
Healthcare
Link
United States of America
Mainz